Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD72 is a type II transmembrane glycoprotein expressed on B lymphocytes, acting as a co-receptor for the B cell receptor (BCR). It contains a C-type lectin-like domain and plays a role in regulating B cell signaling, primarily through its inhibitory function mediated by ITIM motifs and recruitment of SHP-1. CD72 recognizes RNA-containing self-antigens and is implicated in the pathogenesis of autoimmune diseases like SLE. It is also associated with chronic lymphocytic leukemia and may have prognostic value in kidney renal clear cell carcinoma.
CD72 acts as a co-receptor for the B cell receptor (BCR). Its cytoplasmic tail contains ITIM motifs that, upon phosphorylation, recruit SHP-1, leading to downregulation of BCR signaling and inhibition of B cell activation. This mechanism helps maintain self-tolerance, particularly against RNA-containing self-antigens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cluster of Differentiation 72 (CD72).